The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...

马萨诸塞州剑桥 - 目前市值约1.57亿美元的基因编辑公司Editas Medicine, Inc. (NASDAQ:EDIT)宣布战略转型,优先发展其体内CRISPR基因编辑项目,此举源于近期临床前研究的成功。该公司计划将现金储备延长至2027年第二季度,并计划在约两年内实现体内治疗的人体概念验证。根据 InvestingPro ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

【导读】保持基因组稳定性，对细胞平衡至关重要。在这项研究中，团队将CRISPR介导的碱基编辑与集合筛选技术相结合，确定了赖氨酸残基和蛋白质编码基因的大量突变。这些赖氨酸残基和基因的缺失，导致了对DNA损伤剂的敏感性或抗性。2024年12月10日，北京 ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

The San Mateo, California-based company uses CRISPR screening and next-generation sequencing to identify genes that drive cancer through a loss of function when mutated. Most cancer therapies target ...

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria. When such ...